{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:57:18Z","timestamp":1792637838293,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>In patients undergoing percutaneous coronary intervention (PCI), personalised medicine is key to the secondary prevention of ischaemic and bleeding events. To provide an extensive overview of the quality of secondary prevention and of personalised medicine, a\u00a0consortium in the southeastern region of the Netherlands has created a\u00a0PCI registry: the South-East Netherlands Heart Registry (<jats:italic>Zuid-Oost Nederland Hart Registratie<\/jats:italic>, ZON-HR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To visualise and improve personalised secondary prevention post-PCI, focussing on key elements such as antiplatelet treatment, cholesterol management and comorbidities such as diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design and population<\/jats:title>\n            <jats:p>A\u00a0prospective multicentre registry of all consecutive patients undergoing PCI at 4\u00a0participating PCI centres and 3\u00a0referral centres.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Treatment<\/jats:title>\n            <jats:p>Interventional procedures and concomitant pharmaceutical treatment are performed in accordance with the guidelines. The ZON-HR promotes risk stratification after PCI using a\u00a0simplified protocol for a\u00a0personalised antiplatelet strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data collection and quality<\/jats:title>\n            <jats:p>Demographics, laboratory values, baseline procedural characteristics and pharmaceutical treatment data are collected. Outcomes include thromboembolic and bleeding complications and medication changes. Data are pseudonymised, and a\u00a0clinical event committee will review 20% of the adverse events (randomly selected).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Strengths and weaknesses<\/jats:title>\n            <jats:p>This registry represents the entire PCI population and visualises gaps in secondary prevention. Weaknesses are the collection of outcomes and medication changes using mostly patient-reported outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The ZON-HR is a\u00a0comprehensive PCI registry that provides baseline and follow-up data of a\u00a0large PCI cohort in the southeastern region of the Netherlands. The ZON-HR aims to improve secondary prevention after PCI and augment personalised treatment that focusses on key elements of secondary prevention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12471-025-01934-7","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:30:48Z","timestamp":1738866648000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Design and rationale of the South-East Netherlands Heart Registry (ZON-HR)"],"prefix":"10.1007","volume":"33","author":[{"given":"Eva C. I.","family":"Woelders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A. M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J. P.","family":"Luijkx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty J. C.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter S.","family":"Remkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan M.","family":"van Geuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ZON-H.R. investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. C. I.","family":"Woelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A. M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. M.","family":"van Geuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"van Royen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H.","family":"van Wely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Camaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Dimitriu-Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. X.","family":"van Nunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. P.","family":"Luijkx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J. C.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W.","family":"Ruiters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rasoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A. L. J.","family":"Theunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Vriesendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. P. C.","family":"Hoebers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kulekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. J.","family":"Ijsselmuiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. S.","family":"Remkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"Rahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. L. J.","family":"Eerens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. V.","family":"Hemradj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"1934_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg\u00a0T, Hasvold\u00a0P, Henriksson\u00a0M, et\u00a0al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a\u00a0long-term perspective. Eur Heart\u00a0J. 2015;36:1163\u201370.","journal-title":"Eur Heart J"},{"key":"1934_CR2","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","volume":"67","author":"U Baber","year":"2016","unstructured":"Baber\u00a0U, Mehran\u00a0R, Giustino\u00a0G, et\u00a0al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J\u00a0Am Coll Cardiol. 2016;67:2224\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"1934_CR3","first-page":"1175","volume":"105","author":"D Lindholm","year":"2019","unstructured":"Lindholm\u00a0D, Sarno\u00a0G, Erlinge\u00a0D, et\u00a0al. Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. Heart. 2019;105:1175\u201381.","journal-title":"Heart"},{"key":"1934_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa\u00a0F, van Klaveren\u00a0D, James\u00a0S, et\u00a0al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a\u00a0pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025\u201334.","journal-title":"Lancet"},{"key":"1934_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino\u00a0G, Chieffo\u00a0A, Palmerini\u00a0T, et\u00a0al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J\u00a0Am Coll Cardiol. 2016;68:1851\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1934_CR6","doi-asserted-by":"publisher","first-page":"e008708","DOI":"10.1161\/JAHA.118.008708","volume":"7","author":"M Natsuaki","year":"2018","unstructured":"Natsuaki\u00a0M, Morimoto\u00a0T, Yamaji\u00a0K, et\u00a0al. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J\u00a0Am Heart Assoc. 2018;7:e8708.","journal-title":"J Am Heart Assoc"},{"key":"1934_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","volume":"37","author":"MP Bonaca","year":"2016","unstructured":"Bonaca\u00a0MP, Bhatt\u00a0DL, Steg\u00a0PG, et\u00a0al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart\u00a0J. 2016;37:1133\u201342.","journal-title":"Eur Heart J"},{"key":"1934_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh\u00a0RW, Secemsky\u00a0EA, Kereiakes\u00a0DJ, et\u00a0al. Development and validation of a\u00a0prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735\u201349.","journal-title":"JAMA"},{"key":"1934_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti\u00a0J, Wijns\u00a0W, Saraste\u00a0A, et\u00a0al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"1934_CR10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne\u00a0RA, Rossello\u00a0X, Coughlan\u00a0JJ, et\u00a0al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart\u00a0J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"145","key":"1934_CR11","first-page":"e4","volume":"2022","author":"JS Lawton","year":"2021","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e4\u201317.","journal-title":"Cardiology"},{"issue":"148","key":"1934_CR12","first-page":"e9","volume":"2023","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9\u2013119.","journal-title":"Cardiology"},{"issue":"290","key":"1934_CR13","first-page":"140","volume":"2019","author":"ESCNC Societies","year":"2019","unstructured":"Authors\/Task Force M, Guidelines ESCCfP, Societies\u00a0ESCNC. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;2019(290):140\u2013205.","journal-title":"Atherosclerosis"},{"key":"1934_CR14","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference\u00a0BA, Ginsberg\u00a0HN, Graham\u00a0I, et\u00a0al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. A\u00a0consensus statement from the European atherosclerosis society consensus panel. Eur Heart\u00a0J. 2017;38:2459\u201372.","journal-title":"Eur Heart J"},{"key":"1934_CR15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent\u00a0C, Blackwell\u00a0L, et\u00a0al. Efficacy and safety of more intensive lowering of LDL cholesterol: a\u00a0meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1934_CR16","unstructured":"2023. https:\/\/nhr.nl (Created 12.2023)."},{"key":"1934_CR17","volume-title":"Castor","author":"EDC Castor","year":"2019","unstructured":"Castor EDC.\u00a0Castor. Data Capture: Electronic; 2019."},{"key":"1934_CR18","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban\u00a0P, Mehran\u00a0R, Colleran\u00a0R, et\u00a0al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a\u00a0consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart\u00a0J. 2019;40:2632\u201353.","journal-title":"Eur Heart J"},{"key":"1934_CR19","unstructured":"Woelders ECI, Onuma Y, Ninomiya K, et al. Parsimonious versus extensive score: can we simplify bleeding risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy? Eur Heart J. 2019;40:2632\u201353."},{"key":"1934_CR20","unstructured":"NHR. Handboek Nederlandse Hart Registratie Percutane Coronaire Interventie (PCI). 2023."},{"key":"1934_CR21","unstructured":"NHR. Handboek Nederlandse Hart Registratie Uitgebreide specificaties. 2021."},{"key":"1934_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen\u00a0K, Alpert\u00a0JS, Jaffe\u00a0AS, et\u00a0al. Fourth universal definition of myocardial infarction (2018). Eur Heart\u00a0J. 2019;40:237\u201369.","journal-title":"Eur Heart J"},{"key":"1934_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2217\/fca-2021-0085","volume":"18","author":"J Luijkx","year":"2022","unstructured":"Luijkx\u00a0J, Winkler\u00a0P, van \u2019t Hof\u00a0A. Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a\u00a0study rationale. Future Cardiol. 2022;18:265\u201374.","journal-title":"Future Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-01934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:01:33Z","timestamp":1740121293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-01934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-01934-7","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.C.\u00a0Winkler has received an unrestricted grant from Boehringer Ingelheim. P.\u00a0Damman has received research grants from Abbott, Philips and AstraZeneca and is a\u00a0deputy editor of the Netherlands Heart Journal. A.W.J. van \u2019t Hof has received unrestricted grants from AstraZeneca, Medtronic, Abbott Vascular and Boehringer Ingelheim and is an associate editor of the Netherlands Heart Journal. R.J.M. van Geuns has received grants and personal fees from Boston Scientific, Abbott Vascular, AstraZeneca and Amgen and grants from Infraredx. The other authors report no competing interests or disclosures. E.C.\u00a0I.\u00a0Woelders, D.A.\u00a0M.\u00a0Peeters, S.\u00a0Janssen, J.J.\u00a0P.\u00a0Luijkx and W.S.\u00a0Remkes declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}